Question 1

Am I eligible for this trial based on my cancer type and previous treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer clinical trial (NCT06467357). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of the new treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer clinical trial (NCT06467357). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this trial compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer clinical trial (NCT06467357). Contact the study team or your healthcare provider for specific answers.

Question 4

What will my treatment schedule look like if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer clinical trial (NCT06467357). Contact the study team or your healthcare provider for specific answers.

Question 5

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer clinical trial (NCT06467357). Contact the study team or your healthcare provider for specific answers.

Question 6

What should I know about the location and logistics of participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer clinical trial (NCT06467357). Contact the study team or your healthcare provider for specific answers.

What this study is about